Pfizer
-
Vanderbilt team tracks cellular and antibody responses to COVID-19 vaccine
A collaborative team of Vanderbilt researchers has characterized the antigen-specific immune response to the Pfizer SARS-CoV-2 RNA vaccine. The group used multiple single-cell technologies, unbiased machine learning and traditional immunological approaches to track cellular and antibody responses in samples collected over time from a cohort of healthy participants. Read MoreJul 20, 2022
-
VUMC research aids approval of COVID-19 vaccine for young children
The U.S. Food and Drug Administration is expected to authorize Pfizer and Moderna’s COVID-19 vaccines for children as young as 6 months old. Read MoreJun 20, 2022
-
Flu boosts pneumococcal colonization
Influenza and parainfluenza infections – but not other respiratory viruses – increase the risk of acquiring pneumococcal bacteria, the most common cause of severe pneumonia. Read MoreMar 27, 2014
-
Inflammation relief: what’s the delay?
New research offers hope for patients needing the anti-inflammatory benefits of glucocorticoids without the adverse side effects associated with them. Read MoreJun 28, 2011